China Builds Up Capability To Conduct Oncology First-In-Man Studies
This article was originally published in PharmAsia News
SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market
You may also be interested in...
Taking on the risk of a biotech investment in China takes experience, according to Shanghai-based Cenova Ventures, as a recent Series B finance round with Aslan Pharmaceuticals shows.
Global CRO Frontage announced its second clinical site in China and plans for another site in Nanjing to meet increasing early-phase clinical research needs in the country.
The clinical trial process has become a bottleneck for licensing new drugs in China. Now, China’s State FDA has stepped up with a new guideline for Phase I clinical trials– will it help speed up the process?